New data from the KEYNOTE-756 phase 3 clinical trial show that adding the immunotherapy drug pembrolizumab to chemotherapy before and after surgery for breast cancer leads to better outcomes for patients regardless of their age or menopausal status.
New data show pembrolizumab improves breast cancer outcomes regardless of age or menopausal status retrieved 19 March 2024 from https://medicalxpress.com/news/2024-03-pembrolizumab-breast-cancer-outcomes-age.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.6 hours agoUse this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.